Orchid Pharma Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is CEFTAZIDIME (STERILE), with a corresponding US DMF Number 23294.
Remarkably, this DMF maintains an Active status since its submission on December 24, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 29, 2024, and payment made on February 23, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II